Identification of ATP Citrate Lyase As a Positive Regulator of Glycolytic Function in Glioblastomas

Overview

Journal Int J Cancer

Specialty Oncology

Date 2009 Oct 2

PMID 19795461

Citations 61

Authors

Marie E Beckner

Wendy Fellows-Mayle

Zhe Zhang

Naomi R Agostino

Jeffrey A Kant

Billy W Day

Ian F Pollack

Affiliations

Soon will be listed here.

Abstract

Glioblastomas, the most malignant type of glioma, are more glycolytic than normal brain tissue. Robust migration of glioblastoma cells has been previously demonstrated under glycolytic conditions and their pseudopodia contain increased glycolytic and decreased mitochondrial enzymes. Glycolysis is suppressed by metabolic acids, including citric acid which is excluded from mitochondria during hypoxia. We postulated that glioma cells maintain glycolysis by regulating metabolic acids, especially in their pseudopodia. The enzyme that breaks down cytosolic citric acid is ATP citrate lyase (ACLY). Our identification of increased ACLY in pseudopodia of U87 glioblastoma cells on 1D gels and immunoblots prompted investigation of ACLY gene expression in gliomas for survival data and correlation with expression of ENO1, that encodes enolase 1. Queries of the NIH's REMBRANDT brain tumor database based on Affymetrix data indicated that decreased survival correlated with increased gene expression of ACLY in gliomas. Queries of gliomas and glioblastomas found an association of upregulated ACLY and ENO1 expression by chi square for all probe sets (reporters) combined and correlation for numbers of probe sets indicating shared upregulation of these genes. Real-time quantitative PCR confirmed correlation between ACLY and ENO1 in 21 glioblastomas (p < 0.001). Inhibition of ACLY with hydroxycitrate suppressed (p < 0.05) in vitro glioblastoma cell migration, clonogenicity and brain invasion under glycolytic conditions and enhanced the suppressive effects of a Met inhibitor on cell migration. In summary, gene expression data, proteomics and functional assays support ACLY as a positive regulator of glycolysis in glioblastomas.

Citing Articles

Inhibition of ATP Citrate Lyase by Hydroxycitrate-Loaded Exosomes Suppresses the Survival of Lung Adenocarcinoma Cells.

Phutela K, Ahlawat P, Kaur J, Bal A, Singh N, Singh H Appl Biochem Biotechnol. 2025; .

PMID: 40025393 DOI: 10.1007/s12010-025-05204-5.

The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies.

Vijayanathan Y, Ho I Int J Mol Sci. 2025; 26(2).

PMID: 39859381 PMC: 11765942. DOI: 10.3390/ijms26020669.

Role of ATP citrate lyase and its complementary partner on fatty acid synthesis in gastric cancer.

Li C, Liu W, Liu Y, Wang W, Deng W Sci Rep. 2024; 14(1):30043.

PMID: 39627427 PMC: 11615372. DOI: 10.1038/s41598-024-81448-1.

Low-Basicity 5-HT Receptor Ligands from the Group of Cyclic Arylguanidine Derivatives and Their Antiproliferative Activity Evaluation.

Zareba P, Drabczyk A, Wnorowski A, Maj M, Malarz K, Rurka P Int J Mol Sci. 2024; 25(19).

PMID: 39408617 PMC: 11477289. DOI: 10.3390/ijms251910287.

Targeting of REST with rationally-designed small molecule compounds exhibits synergetic therapeutic potential in human glioblastoma cells.

Panina S, Schweer J, Zhang Q, Raina G, Hardtke H, Kim S BMC Biol. 2024; 22(1):83.

PMID: 38609948 PMC: 11015551. DOI: 10.1186/s12915-024-01879-0.

References

Luk C, Tjan E, Tannock I . Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J Natl Cancer Inst. 1990; 82(8):684-92. DOI: 10.1093/jnci/82.8.684. View

Seymour Z, Panigrahy A, Finlay J, Nelson Jr M, Bluml S . Citrate in pediatric CNS tumors?. AJNR Am J Neuroradiol. 2008; 29(5):1006-11. PMC: 8128606. DOI: 10.3174/ajnr.A1018. View

Oudard S, Boitier E, Miccoli L, Rousset S, Dutrillaux B, Poupon M . Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res. 1997; 17(3C):1903-11. View

Rafalowska U . Transport of malate and citrate into rat brain mitochondria under hypoxia and anesthesia. Neurochem Res. 1979; 4(3):355-64. DOI: 10.1007/BF00963805. View

Brat D, Van Meir E . Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest. 2004; 84(4):397-405. DOI: 10.1038/labinvest.3700070. View

Beckner M, Stracke M, Liotta L, Schiffmann E . Glycolysis as primary energy source in tumor cell chemotaxis. J Natl Cancer Inst. 1990; 82(23):1836-40. DOI: 10.1093/jnci/82.23.1836. View

Oudard S, Arvelo F, Miccoli L, Apiou F, Dutrillaux A, Poisson M . High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer. 1996; 74(6):839-45. PMC: 2074724. DOI: 10.1038/bjc.1996.446. View

Vaupel P, Kallinowski F, Okunieff P . Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989; 49(23):6449-65. View

Colofiore J, Stolfi R, Nord L, Martin D . Biochemical modulation of tumor cell energy. IV. Evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically-induced tumor regression. Biochem Pharmacol. 1995; 50(11):1943-8. DOI: 10.1016/0006-2952(95)02094-2. View

10.

Brat D, Castellano-Sanchez A, Hunter S, Pecot M, Cohen C, Hammond E . Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 2004; 64(3):920-7. DOI: 10.1158/0008-5472.can-03-2073. View

11.

Ma P, Jagadeeswaran R, Jagadeesh S, Tretiakova M, Nallasura V, Fox E . Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005; 65(4):1479-88. DOI: 10.1158/0008-5472.CAN-04-2650. View

12.

Sanna K, Rofstad E . Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer. 1994; 58(2):258-62. DOI: 10.1002/ijc.2910580219. View

13.

Hatzivassiliou G, Zhao F, Bauer D, Andreadis C, Shaw A, Dhanak D . ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005; 8(4):311-21. DOI: 10.1016/j.ccr.2005.09.008. View

14.

Pfeiffer T, Schuster S, Bonhoeffer S . Cooperation and competition in the evolution of ATP-producing pathways. Science. 2001; 292(5516):504-7. DOI: 10.1126/science.1058079. View

15.

Lill U, Schreil A, EGGERER H . Isolation of enzymically active fragments formed by limited proteolysis of ATP citrate lyase. Eur J Biochem. 1982; 125(3):645-50. DOI: 10.1111/j.1432-1033.1982.tb06731.x. View

16.

Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M . ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res. 2008; 68(20):8547-54. DOI: 10.1158/0008-5472.CAN-08-1235. View

17.

Preuss H, Bagchi D, Bagchi M, Rao C, Dey D, Satyanarayana S . Effects of a natural extract of (-)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. Diabetes Obes Metab. 2004; 6(3):171-80. DOI: 10.1111/j.1462-8902.2004.00328.x. View

18.

Swinnen J, Beckers A, Brusselmans K, Organe S, Segers J, Timmermans L . Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res. 2005; 65(6):2441-8. DOI: 10.1158/0008-5472.CAN-04-3025. View

19.

Dringen R, Gebhardt R, Hamprecht B . Glycogen in astrocytes: possible function as lactate supply for neighboring cells. Brain Res. 1993; 623(2):208-14. DOI: 10.1016/0006-8993(93)91429-v. View

20.

Berthou S, Aebersold D, Schmidt L, Stroka D, Heigl C, Streit B . The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene. 2004; 23(31):5387-93. DOI: 10.1038/sj.onc.1207691. View